Industry News

NuVasive, Inc., a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the appointment of Mike O'Halleran and Pat Miles to the Company's Board of Directors effective August 1, 2016. Mr. O'Halleran will serve as an independent director of the Company and member of the Board's Audit Committee. Miles currently serves as president and chief operating officer..."/>
Michael D. O'Halleran and Patrick S. Miles Elected to NuVasive Board of Directors
Aptevo Therapeutics Inc., a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the completion of its separation from Emergent BioSolutions Inc. and its launch as an independent, publicly traded corporation. Aptevo common stock will begin "regular way" trading under the symbol“ APVO” on the Nasdaq Global Select Market today, August 1, 2016.. “Today is the culmination of the hard work of our entire team at Aptevo, and..."/>
Aptevo Therapeutics Completes Separation from Emergent BioSolutions
Enumeral Biomedical Holdings, Inc., a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that on July 29, 2016 the Company sold 12% Senior Secured Promissory Notes in a private placement offering to certain accredited investors in the aggregate principal amount of $3,038,256, before deducting placement agent fees and..."/>
Enumeral Announces Sale of 12% Senior Secured Promissory Notes
Mylan Launches Generic Propecia® Tablets
Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today the appointment of Yue Alexander Wu, Ph.D to its Board of Directors. Wu will also serve as a member of the Compensation Committee and Audit Committee of the Board. Doug Ebersole has resigned as a member of the Board for personal reasons."/>
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
Vanda Pharmaceuticals Inc. today announced that HETLIOZ ® is now available for the treatment of Non-24-Hour Sleep-Wake Disorder in Germany. "The launch of HETLIOZ in Germany reflects our continued focus to bring a treatment option to Non-24 patients across the globe," said Gian Piero Reverberi, Vanda's Senior Vice President and Chief Commercial Officer. "We are very pleased with our first HETLIOZ launch outside of the United States and look..."/>
HETLIOZ® is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany
BioDelivery Sciences International, Inc. announced that it will host a conference call and webcast on Tuesday, August 9, at 8:00 A.M. Eastern time. During the call, management will review BDSI's second quarter 2016 financial results and provide a business update. BioDelivery Sciences International, Inc. is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine."/>
BioDelivery Sciences to Host Conference Call and Webcast of Second Quarter 2016 Results on Tuesday, August 9
Shire plc announced that the U.S. Food and Drug Administration has approved the BAXJECT III reconstitution system for ADYNOVATE."/>
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Evogene Ltd., a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, announced today that Assaf Kacen, Chief Operating Officer, will participate at the Piper Jaffray Global Agriculture Symposium taking place in Minneapolis, Minnesota, August 2, 2016.. Kacen will take part at the Gene Editing panel which will take place on Tuesday, August 2, at 2:00 pm. He will discuss the potential of genome..."/>
Evogene to Participate at Piper Jaffray Global Agriculture Symposium
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, today announced the election of Timothy C. Barabe to the company’ s Board of Directors. Most recently serving as chief financial officer and executive vice president at Affymetrix Inc., Mr. Barabe has extensive experience in the life sciences industry, having held a broad range of financial..."/>
Selecta Biosciences Appoints Timothy C. Barabe to Board of Directors
Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's second quarter 2016 financial results will be released on Thursday, August 4, 2016 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, August 4, 2016, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.."/>
Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Glenn Noronha, Ph.D., has been promoted to Chief Scientific Officer and Jennifer M. Kissner, Ph.D., has been promoted to Vice President, Clinical Development. Noronha and Kissner will assume their roles immediately and will report to Daniel H. White, CEO and President of..."/>
Clearside Biomedical, Inc. Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development
Emergent BioSolutions Inc. today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. through the distribution of all of the shares of Aptevo common stock to the holders of Emergent BioSolutions common stock. As a result of the spin-off, Aptevo is now an independent public company and listed on the Nasdaq Global Select Market under the ticker symbol“ APVO.”. “Completion of this spin-off is a significant..."/>
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics
pSivida Corp., a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery, America’ s leading specialty hospital devoted to orthopedics and rheumatology, announce the opening of an investigational new drug application to begin an investigator-sponsored clinical study of a sustained-release implant to treat severe osteoarthritis of the knee. The implant is designed to..."/>
PSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
Amedisys, Inc., one of the nation’ s leading home health care and hospice companies, today announced that it has signed a definitive agreement to acquire Professional Profiles, Inc., a personal care company with corporate headquarters in Danvers, Massachusetts. Under the terms of the agreement, Amedisys will acquire substantially all of the assets of Professional Profiles, Inc., for $4.4 million. The transaction is expected to close on September 1, 2016.."/>
Amedisys Announces Definitive Agreement to Acquire Professional Profiles, Inc.
Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the first patients have been dosed in the Company’ s Phase 2 STAR 1 clinical trial, a randomized, multi-center, multi-dose study to evaluate ZYN002 cannabidiol gel in adult epilepsy patients with refractory focal seizures. ZYN002 CBD gel is the first and only..."/>
Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures
AcelRx Pharmaceuticals, Inc. today announced that the Company and its investigators will be presenting top-line results from the initial cohort of 40 patients in single-arm, open-label Phase 3 SAP302 study, which assessed ARX-04 as a treatment for moderate-to-severe acute pain in adults who presented to the emergency department with trauma or injury. These data will be presented at the 7th World Congress of Mountain& Wilderness..."/>
AcelRx Pharmaceuticals to Present Initial Results of Phase 3 Study of ARX?04 at World Congress of Mountain & Wilderness Medicine
Seattle Genetics, Inc. today announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS in patients with..."/>
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Sucampo Pharmaceuticals reported on Friday that Paul Edick has been appointed to its board of directors with effect from 1 August 2016.. Currently, Edick is a director at PDL BioPharma, NewLink Genetics and Neos Therapeutics; chairman of Iterum Therapeutics' board as well as founding partner of 3 G Advisors. Edick served as chief executive officer and a board member of Durata Therapeutics, from July 2010 to November 2014.."/>
Sucampo Pharmaceuticals elects Paul Edick to its board
INC Research Holdings, Inc., a leading global Phase I to Phase IV contract research organization, today announced that certain of its existing stockholders, namely affiliates of Avista Capital Partners, L.P. and affiliates of Ontario Teachers’ Pension Plan, intend to offer for sale in an underwritten secondary offering 5,000,000 shares of the Company’ s Class A common stock pursuant to the Company’ s shelf registration statement filed with the Securities..."/>
INC Research Announces Secondary Offering
Chembio Diagnostics disclosed on Friday that it has priced a higher underwritten public offering of 2,000,000 shares of its common stock at USD6.00 per share for total gross proceeds of approximately USD12m. The company has provided the underwriters with a 30- day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any. Upon deducting the underwriters' discount and other estimated offering expenses,..."/>
Chembio Diagnostics prices upsized public offering of 2m common stock
Evoke Pharma said on Friday that it expects approximately USD10m from its registered direct offering of common stock issued at the market price. Under the terms of the offering, the company will issue approximately USD10m of registered shares of common stock at a purchase price of USD3.0825 per share. For each share of common stock purchased by an investor, such investor will receive from the company an unregistered warrant to purchase 0.50 shares of..."/>
Evoke Pharma anticipates USD10m from registered direct offering of common stock at the market price
SteadyMed revealed on Friday that it has entered into definitive agreements to sell common stock and warrants to purchase shares its common stock for aggregate gross proceeds of up to USD32m under a two-tranche private placement subject to customary closing conditions. At the first closing, the company will sell 6.6 m ordinary shares and warrants to purchase approximately 6.6 m ordinary shares for aggregate gross proceeds of USD21m."/>
SteadyMed closes up to USD32m in private placement of its common stock and warrants
Agilent Technologies Inc. will release third-quarter fiscal 2016 financial results after the stock market closes on Aug. 17. The company will host a live webcast of its investor conference call in listen-only mode. Date: Wednesday, Aug. 17, 2016."/>
Agilent Technologies to Host Webcast of Third-Quarter Fiscal Year 2016 Financial Results Conference Call

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary544 Articles
Information Technology456 Articles
Financials395 Articles
Industrials264 Articles
Health Care255 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.